Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

BACKGROUND: Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial. OBJECTIVE: To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow‐on randomised controlled trial (CLASSIC I...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Sandborn, W J, Hanauer, S B, Rutgeerts, P, Fedorak, R N, Lukas, M, MacIntosh, D G, Panaccione, R, Wolf, D, Kent, J D, Bittle, B, Li, J, Pollack, P F
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 2007
Gaiak:
Inflammatory Bowel Disease
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2701613/
https://ncbi.nlm.nih.gov/pubmed/17299059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2006.106781
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak